--- title: "Caredex | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 117.7 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/284442892.md" datetime: "2026-04-28T20:19:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284442892.md) - [en](https://longbridge.com/en/news/284442892.md) - [zh-HK](https://longbridge.com/zh-HK/news/284442892.md) --- # Caredex | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 117.7 M Revenue: As of FY2026 Q1, the actual value is USD 117.7 M, beating the estimate of USD 104.46 M. EPS: As of FY2026 Q1, the actual value is USD 0.05, beating the estimate of USD -0.02. EBIT: As of FY2026 Q1, the actual value is USD 868 K. #### Segment Revenue - **Total Revenue**: CareDx, Inc. reported total revenue of $117.7 million for the three months ended March 31, 2026, an increase of 39% year-over-year compared to $84.7 million for the same period in 2025 . - **Testing Services Revenue**: Increased by $29.5 million, or 48%, to $91.4 million for the three months ended March 31, 2026, from $61.9 million in the prior year . This was primarily driven by a 17% increase in testing services volume to approximately 54,900, including $17.7 million of increased net collections from prior periods, partially offset by a -$3.4 million reduction due to an increase in refund reserves . Testing services revenue constituted 78% of total revenue for the three months ended March 31, 2026, and 73% for the same period in 2025 . - **Product Revenue**: Decreased by -$0.5 million, or -4%, to $10.3 million for the three months ended March 31, 2026, compared to $10.8 million in the prior year, mainly due to lower sales of commercial NGS-based kitted solutions . Product revenue accounted for 9% of total revenue for the three months ended March 31, 2026, and 13% for the same period in 2025 . - **Patient and Digital Solutions Revenue**: Increased by $4.0 million, or 33%, to $16.0 million for the three months ended March 31, 2026, from $12.0 million in the prior year, primarily due to higher pharmacy sales and growth in digital solutions, particularly from expanded Ottr software customer base . This segment represented 14% of total revenue for both the three months ended March 31, 2026, and 2025 . #### Operational Metrics - **Net Income (Loss)**: The company reported a net income of $2.8 million for the three months ended March 31, 2026, a significant improvement from a net loss of -$10.4 million for the same period in 2025 . - **Operating Expenses**: Total operating expenses increased by $18.4 million, or 19%, to $116.5 million for the three months ended March 31, 2026, compared to $98.1 million in the prior year . - **Cost of Testing Services**: Increased by $2.0 million, or 13%, to $17.1 million for the three months ended March 31, 2026, compared to $15.1 million in 2025, mainly due to higher testing services volume, partially offset by efficiency measures . - **Cost of Product**: Decreased by -$0.8 million, or -13%, to $4.8 million for the three months ended March 31, 2026, from $5.6 million in 2025, primarily due to lower sales and improved manufacturing efficiencies . - **Cost of Patient and Digital Solutions**: Increased by $4.0 million, or 52%, to $11.7 million for the three months ended March 31, 2026, from $7.7 million in 2025, mainly due to increased cost of goods from the pharmacy business . - **Research and Development (R&D)**: Increased by $2.9 million, or 16%, to $21.4 million for the three months ended March 31, 2026, compared to $18.5 million in 2025, primarily due to increases in personnel-related costs and consulting/licensing expenses . - **Sales and Marketing**: Increased by $7.4 million, or 32%, to $30.4 million for the three months ended March 31, 2026, compared to $23.0 million in 2025, driven by higher personnel-related costs and marketing expenses . - **General and Administrative (G&A)**: Increased by $7.7 million, or 34%, to $30.5 million for the three months ended March 31, 2026, compared to $22.8 million in 2025, primarily due to increases in personnel-related costs, stock-based compensation, and legal/consulting expenses . - **Litigation Settlement Expense**: Decreased by -$4.8 million, or -89%, to $0.6 million for the three months ended March 31, 2026, compared to $5.4 million in 2025 . This decrease was mainly due to a $5.4 million settlement related to a Securities Class Action lawsuit in 2025, partially offset by a $0.6 million settlement for a Derivative Actions Lawsuit in 2026 . - **Income from Operations**: The company reported an income from operations of $1.2 million for the three months ended March 31, 2026, compared to a loss from operations of -$13.4 million for the same period in 2025 . - **Interest Income, net**: Decreased by -$0.9 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to a decrease in cash, cash equivalents, and marketable securities . - **Other (Expense) Income, net**: Decreased by -$0.6 million for the three months ended March 31, 2026, compared to the same period in 2025, primarily due to foreign exchange losses . #### Cash Flow - **Net Cash Provided by Operating Activities**: $4.3 million for the three months ended March 31, 2026, compared to net cash used in operating activities of -$26.6 million for the same period in 2025 . - **Net Cash Provided by Investing Activities**: $11.1 million for the three months ended March 31, 2026, primarily from $54.7 million in maturities of marketable securities, partially offset by $39.9 million in purchases of marketable securities and $3.8 million in property and equipment additions . This compares to $1.3 million provided by investing activities in 2025 . - **Net Cash Used in Financing Activities**: -$2.9 million for the three months ended March 31, 2026, mainly due to -$2.5 million in taxes paid for net share settlements of restricted stock units and -$1.5 million for contingent consideration payments, partially offset by $1.0 million from employee stock purchase plan and $0.1 million from stock option exercises . This compares to -$0.6 million used in financing activities in 2025 . #### Unique Metrics - **Testing Services Volume**: Approximately 54,900 tests for the three months ended March 31, 2026, an increase of 17% year-over-year . - **Average Revenue per Test**: Approximately $1,660, including $14 million in prior period revenue . - **Cash, Cash Equivalents, and Marketable Securities**: $198.1 million as of March 31, 2026, with no debt outstanding . #### Future Outlook and Strategy CareDx, Inc. entered into a Purchase Agreement on April 15, 2026, to sell its kitted laboratory products business and related software for $170 million in cash, subject to customary adjustments . The company also agreed to acquire Naveris, Inc. for an aggregate of $160.0 million in cash at closing, plus up to $100.0 million in additional cash consideration contingent on achieving specified revenue-based milestones during fiscal years 2026 and 2027 . Additionally, CareDx, Inc.’s Board of Directors authorized a new share repurchase program on April 24, 2026, allowing for the repurchase of up to $100.0 million in common stock over two years, commencing April 30, 2026, with $12.2 million remaining available under the May 2025 Repurchase Program as of March 31, 2026 . ### Related Stocks - [CDNA.US](https://longbridge.com/en/quote/CDNA.US.md) ## Related News & Research - [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md)